We use cookies to see how investors use El Fondo and make its tools, data and markets better for you. You can accept or reject; essential cookies always stay on. Privacy Policy
Trades about 223% below its sector, cheaper than its peers on earnings.
BGI Genomics Co., Ltd. operates as an international supplier of genetic testing solutions and sequencing services. The company caters to a broad clientele, encompassing medical and research facilities, as well as other public and private organizations, both within China and across the globe. Its comprehensive service portfolio includes DNA, RNA, and tailored sequencing options. Additionally, it offers a suite of specialized genetic tests such as non-invasive prenatal testing (NIPT), reproductive health screening, and newborn genetic screening, alongside clinical exome sequencing. BGI Genomics also develops clinical and research-focused solutions for the field of oncology. During the COVID-19 pandemic, the firm provided crucial laboratory solutions for the detection and diagnosis of suspected cases, including SARS-CoV-2 IgM and IgG antibody detection kits, and real-time fluorescent RT-PCR kits. Their expertise spans numerous research domains, including but not limited to agriculture and food science, cancer research, metagenomics, reproductive health, biomarker discovery, and drug development. Established in 1999, the company initially operated under the name Shenzhen BGI Medicine Co., Ltd. before officially changing to BGI Genomics Co., Ltd. in 2015. Its corporate headquarters are located in Shenzhen, China.
Loading the full price history…
Run your own numbersPast performance is not a forecast.
Save 300676.SZ and get told when something moves.
Get updates
A clear, direct weekly summary.
Learn the fundamentals behind this asset.
A stock is a fraction of ownership in a real company. Buy one share and you own a piece (usually a tiny piece) of every desk, factory, contract and brand the company runs. The price moves because the market keeps revising what that whole pie is worth.
The price-to-earnings ratio is how much investors are paying for one dollar of a company's profit. A multiple, never an absolute. Always compared to something: a sector, a region, the company's own past.
Dividend yield is the annual income a stock or ETF pays out, expressed as a percentage of what you paid for it. It is the visible part of total return: the cash that lands in your account every quarter, and the lever most retail investors actually feel.
Market cap is shares times price. A simple formula that produces wildly unequal numbers: a single US tech name can be worth more than every company on a LATAM exchange combined.
